{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:34:40Z","timestamp":1792503280989,"version":"4.5.0"},"reference-count":110,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.autrev.2024.103687","type":"journal-article","created":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T10:33:28Z","timestamp":1731234808000},"page":"103687","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Harnessing the potential of CAR-T cell in lupus treatment: From theory to practice"],"prefix":"10.1016","volume":"23","author":[{"given":"Tamim","family":"Alsuliman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zora","family":"Marjanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doron","family":"Rimar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Tarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadej","family":"Avcin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Hagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Farge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2024.103687_bb0005","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103687_bb0010","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/S0140-6736(19)30546-X","article-title":"Novel paradigms in systemic lupus erythematosus","volume":"393","author":"D\u00f6rner","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2024.103687_bb0015","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00296-022-05183-4","article-title":"Global and regional prevalence and incidence of systemic lupus erythematosus in low-and-middle income countries: a systematic review and meta-analysis","volume":"42","author":"Fatoye","year":"2022","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2024.103687_bb0020","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/rheumatology\/keac610","article-title":"The global epidemiology of SLE: narrowing the knowledge gaps","volume":"62","author":"Barber","year":"2023","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.autrev.2024.103687_bb0025","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/joim.12395","article-title":"Human autoimmune diseases: a comprehensive update","volume":"278","author":"Wang","year":"2015","journal-title":"J Intern Med"},{"key":"10.1016\/j.autrev.2024.103687_bb0030","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European league against rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103687_bb0035","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrrheum.2015.159","article-title":"What is damaging the kidney in lupus nephritis?","volume":"12","author":"Davidson","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2024.103687_bb0040","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103687_bb0045","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103687_bb0050","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1523-1755.2004.00443.x","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited","volume":"65","author":"Weening","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2024.103687_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/849684","article-title":"Lupus nephritis: an overview of recent findings","volume":"2012","author":"De Zubiria","year":"2012","journal-title":"Autoimmune Dis"},{"key":"10.1016\/j.autrev.2024.103687_bb0060","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/art.40729","article-title":"All-cause and cause-specific mortality trends of end-stage renal disease due to lupus nephritis from 1995 to 2014","volume":"71","author":"Jorge","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2024.103687_bb0065","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2023-001114","article-title":"Clinical trial outcomes for SLE: what we have and what we need","volume":"11","author":"Arnaud","year":"2024","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.autrev.2024.103687_bb0070","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejim.2023.02.004","article-title":"Mortality and causes of death in systemic lupus erythematosus over the last decade: data from a large population-based study","volume":"112","author":"Zen","year":"2023","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.autrev.2024.103687_bb0075","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1093\/rheumatology\/keaa917","article-title":"Mortality in SLE patients compared with population controls in Finland in years 2000\u20132015","volume":"60","author":"Elfving","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2024.103687_bb0080","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis: the euro-lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2024.103687_bb0085","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40265-022-01824-x","article-title":"Refractory systemic lupus erythematosus: identification and pharmacological management","volume":"83","author":"Roccatello","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.autrev.2024.103687_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102476","article-title":"Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee","volume":"69","author":"Greco","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.autrev.2024.103687_bb0095","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nm.2752","article-title":"Taming lupus\u2014a new understanding of pathogenesis is leading to clinical advances","volume":"18","author":"Liu","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2024.103687_bb0100","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41590-020-0677-6","article-title":"Autoimmunity and organ damage in systemic lupus erythematosus","volume":"21","author":"Tsokos","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2024.103687_bb0105","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/S0140-6736(14)60128-8","article-title":"Systemic lupus erythematosus","volume":"384","author":"Lisnevskaia","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2024.103687_bb0110","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-immunol-101921-042422","article-title":"Systemic lupus erythematosus pathogenesis: interferon and beyond","volume":"41","author":"Caielli","year":"2023","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.autrev.2024.103687_bb0115","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1191\/096120301670679959","article-title":"Early damage as measured by the SLICC\/ACR damage index is a predictor of mortality in systemic lupus erythematosus","volume":"10","author":"Rahman","year":"2001","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2024.103687_bb0120","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nrneph.2016.71","article-title":"The role of neutrophils and NETosis in autoimmune and renal diseases","volume":"12","author":"Gupta","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.autrev.2024.103687_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103072","article-title":"Kidney disease in antiphospholipid antibody syndrome: risk factors, pathophysiology and management","volume":"21","author":"Scheen","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2024.103687_bb0130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1615\/CritRevImmunol.2018025213","article-title":"SLE-associated defects promote altered T cell function","volume":"37","author":"Crispin","year":"2017","journal-title":"Crit Rev Immunol"},{"key":"10.1016\/j.autrev.2024.103687_bb0135","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1136\/annrheumdis-2021-221464","article-title":"Immune cell multiomics analysis reveals contribution of oxidative phosphorylation to B-cell functions and organ damage of lupus","volume":"81","author":"Takeshima","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103687_bb0140","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.imlet.2023.03.003","article-title":"IgD-CD27- double negative (DN) B cells: origins and functions in health and disease","volume":"255","author":"Beckers","year":"2023","journal-title":"Immunol Lett"},{"key":"10.1016\/j.autrev.2024.103687_bb0145","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.immuni.2018.08.015","article-title":"Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus","volume":"49","author":"Jenks","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2024.103687_bb0150","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/s41590-020-0743-0","article-title":"Mapping systemic lupus erythematosus heterogeneity at the single-cell level","volume":"21","author":"Nehar-Belaid","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2024.103687_bb0155","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.3899\/jrheum.101088","article-title":"Prognostic indicators of hospitalized patients with systemic lupus erythematosus: a large retrospective multicenter study in China","volume":"38","author":"Feng","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2024.103687_bb0160","article-title":"Long-term survival and death causes of systemic lupus erythematosus in China: a systemic review of observational studies","volume":"94","author":"Wang","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2024.103687_bb0165","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s41927-023-00358-3","article-title":"Safety and efficacy of biological agents in the treatment of systemic lupus erythematosus (SLE)","volume":"7","author":"Chan","year":"2023","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.autrev.2024.103687_bb0170","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2014-000031","article-title":"Clinical, laboratory and health-related quality of life correlates of systemic lupus erythematosus responder index response: a post hoc analysis of the phase 3 belimumab trials","volume":"1","author":"Furie","year":"2014","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.autrev.2024.103687_bb0175","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of Anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103687_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.980079","article-title":"Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment","volume":"13","author":"Kirou","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2024.103687_bb0185","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.autrev.2024.103687_bb0190","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/art.42784","article-title":"CD19 chimeric antigen receptor T cell treatment: unraveling the role of B cells in systemic lupus erythematosus","volume":"76","author":"Taubmann","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2024.103687_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2024.102442","article-title":"New insights into the mechanisms regulating plasma cell survival and longevity","volume":"88","author":"Khamyath","year":"2024","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.autrev.2024.103687_bb0200","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1631\/jzus.B1200057","article-title":"Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis","volume":"13","author":"Lan","year":"2012","journal-title":"J Zhejiang Univ Sci B"},{"key":"10.1016\/j.autrev.2024.103687_bb0205","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/mr\/roac007","article-title":"Rituximab in the real-world treatment of lupus nephritis: a retrospective cohort study in Japan","volume":"33","author":"Tanaka","year":"2023","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2024.103687_bb0210","doi-asserted-by":"crossref","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","author":"Tur","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103687_bb0215","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/ajt.12220","article-title":"A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function","volume":"13","author":"Kamburova","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.autrev.2024.103687_bb0220","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a lupus low disease activity state (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103687_bb0225","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"Van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.autrev.2024.103687_bb0230","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1002\/art.22810","article-title":"Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy","volume":"56","author":"Anolik","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2024.103687_bb0235","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.3390\/cells10051190","article-title":"B cell activation and escape of tolerance checkpoints: recent insights from studying autoreactive B cells","volume":"10","author":"Bonasia","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.autrev.2024.103687_bb0240","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nm1763","article-title":"The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis","volume":"14","author":"Neubert","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2024.103687_bb0245","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13075-018-1578-z","article-title":"Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus","volume":"20","author":"Cole","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2024.103687_bb0250","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103687_bb0255","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103687_bb0260","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1080\/14397595.2018.1432331","article-title":"Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus","volume":"28","author":"Ishii","year":"2018","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2024.103687_bb0265","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/s41591-023-02479-1","article-title":"Daratumumab monotherapy for refractory lupus nephritis","volume":"29","author":"Roccatello","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2024.103687_bb0270","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1073\/pnas.82.8.2483","article-title":"Rationale for bone marrow transplantation in the treatment of autoimmune diseases","volume":"82","author":"Ikehara","year":"1985","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.autrev.2024.103687_bb0275","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1182\/blood-2007-03-081497","article-title":"Reversal of autoimmune disease in lupus-prone New Zealand black\/New Zealand white mice by nonmyeloablative transplantation of purified allogeneic hematopoietic stem cells","volume":"110","author":"Smith-Berdan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2024.103687_bb0280","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1177\/096120339700600613","article-title":"Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration","volume":"6","author":"Marmont","year":"1997","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2024.103687_bb0285","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1191\/0961203304lu525oa","article-title":"Autologous stem cell transplantation for systemic lupus erythematosus","volume":"13","author":"Jayne","year":"2004","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2024.103687_bb0290","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jama.295.5.527","article-title":"Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus","volume":"295","author":"Burt","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2024.103687_bb0295","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/0961203312470729","article-title":"Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: data from the European Group for Blood and Marrow Transplantation registry","volume":"22","author":"Alchi","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2024.103687_bb0300","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2215\/CJN.10570918","article-title":"Autologous hematopoietic stem cell transplantation for refractory lupus nephritis","volume":"14","author":"Huang","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2024.103687_bb0305","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3324\/haematol.2009.013458","article-title":"Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years\u2019 experience from the European Group for Blood and Marrow Transplantation Working Party on autoimmune diseases","volume":"95","author":"Farge","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.autrev.2024.103687_bb0310","doi-asserted-by":"crossref","first-page":"6346","DOI":"10.4049\/jimmunol.0901773","article-title":"Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-\u03b2-producing CD8+ Treg cells are associated with immunological remission of lupus","volume":"183","author":"Zhang","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2024.103687_bb0315","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.autrev.2024.103687_bb0320","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.autrev.2024.103687_bb0325","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103687_bb0330","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103687_bb0335","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","article-title":"Engineering CAR-T cells","volume":"5","author":"Zhang","year":"2017","journal-title":"Biomark Res"},{"key":"10.1016\/j.autrev.2024.103687_bb0340","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.omtm.2019.11.018","article-title":"Optimizing CAR-T cell manufacturing processes during pivotal clinical trials","volume":"16","author":"Tyagarajan","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.autrev.2024.103687_bb0345","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.ymthe.2018.05.007","article-title":"PiggyBac-engineered T cells expressing CD19-specific CARs that lack IgG1 fc spacers have potent activity against B-ALL xenografts","volume":"26","author":"Bishop","year":"2018","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"10.1016\/j.autrev.2024.103687_bb0350","first-page":"113","article-title":"CRISPR takes the front seat in CART-cell development","volume":"35","author":"Manriquez-Roman","year":"2021","journal-title":"BioDrugs Clin Immunother Biopharm Gene Ther"},{"key":"10.1016\/j.autrev.2024.103687_bb0355","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40364-022-00359-3","article-title":"Donor T cells for CAR T cell therapy","volume":"10","author":"Tang","year":"2022","journal-title":"Biomark Res"},{"key":"10.1016\/j.autrev.2024.103687_bb0360","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.141293","article-title":"A soluble activator that favors the ex vivo expansion of CD8+CD27+ T cells","volume":"5","author":"Matus","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.autrev.2024.103687_bb0365","series-title":"The EBMT handbook: Hematopoietic cell transplantation and cellular therapies","author":"Sureda","year":"2024"},{"key":"10.1016\/j.autrev.2024.103687_bb0370","series-title":"Chimeric antigen recept. T cells","first-page":"203","article-title":"Approaches of T cell activation and differentiation for CAR-T cell therapies","volume":"vol. 2086","author":"Schwab","year":"2020"},{"key":"10.1016\/j.autrev.2024.103687_bb0375","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.886637","article-title":"Influence of culture conditions on ex vivo expansion of T lymphocytes and their function for therapy: current insights and open questions","volume":"10","author":"Sudarsanam","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.autrev.2024.103687_bb0380","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1034707","article-title":"Next generations of CAR-T cells - new therapeutic opportunities in hematology?","volume":"13","author":"Tomasik","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2024.103687_bb0385","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1084\/jem.181.5.1653","article-title":"Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes","volume":"181","author":"Brocker","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2024.103687_bb0390","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","article-title":"Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells","volume":"112","author":"Till","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2024.103687_bb0395","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2024.103687_bb0400","doi-asserted-by":"crossref","DOI":"10.3892\/ol.2020.11897","article-title":"Cluster of differentiation 19 chimeric antigen receptor T-cell therapy in pediatric acute lymphoblastic leukemia (review)","author":"Fu","year":"2020","journal-title":"Oncol Lett"},{"key":"10.1016\/j.autrev.2024.103687_bb0405","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103687_bb0410","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease \u2014 a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103687_bb0415","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","article-title":"Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma","volume":"26","author":"Brudno","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2024.103687_bb0420","first-page":"208","article-title":"POS0007\u00a0KYV-101, a fully human CD19 CAR t cell generated from autoimmune patient lymphocytes, demonstrates CAR-mediated and CD19-dependent activity against autologous b cells","volume":"82","author":"Park","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103687_bb0425","article-title":"Fully human anti-CD19 CAR T cells derived from systemic lupus erythematosus patients exhibit cytotoxicity with reduced inflammatory cytokine production","volume":"S2666636724002975","author":"Dingfelder","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.autrev.2024.103687_bb0430","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2024.103687_bb0435","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","article-title":"Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus","volume":"18","author":"Jin","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.autrev.2024.103687_bb0440","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/biomedicines10020287","article-title":"CAR-T regulatory (CAR-Treg) cells: engineering and applications","volume":"10","author":"Arjomandnejad","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.autrev.2024.103687_bb0445","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1038\/s41467-024-46448-9","article-title":"Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in systemic lupus erythematosus","volume":"15","author":"Doglio","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2024.103687_bb0450","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.autrev.2024.103687_bb0455","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/annrheumdis-2022-eular.4281","article-title":"POS0463 reengineering chimeric antigen receptor t cells for targeted therapy of lupus nephritis","volume":"81","author":"Sol\u00e9-Marc\u00e9","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103687_bb0460","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2024.103687_bb0465","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.179433","article-title":"Selective CAR T cell\u2013mediated B cell depletion suppresses IFN signature in SLE","volume":"9","author":"Wilhelm","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.autrev.2024.103687_bb0470","first-page":"7","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2024.103687_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101459","article-title":"Resistance against anti-CD19 and anti-BCMA CAR T cells: recent advances and coping strategies","volume":"22","author":"Atilla","year":"2022","journal-title":"Transl Oncol"},{"key":"10.1016\/j.autrev.2024.103687_bb0480","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2024.103687_bb0485","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1182\/blood-2023-186669","article-title":"CD19\/BCMA CAR-T cell therapy for refractory systemic lupus erythematosus - safety and preliminary efficacy data from a phase I clinical study","volume":"142","author":"Feng","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2024.103687_bb0490","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1158\/2643-3230.BCD-22-0074","article-title":"Anti-BCMA\/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy","volume":"4","author":"Garfall","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.autrev.2024.103687_bb0495","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1007\/s12015-021-10251-6","article-title":"Treatment of systemic lupus erythematosus using BCMA-CD19 compound CAR","volume":"17","author":"Zhang","year":"2021","journal-title":"Stem Cell Rev Rep"},{"key":"10.1016\/j.autrev.2024.103687_bb0500","volume":"S1470204524000949","author":"Lin","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.autrev.2024.103687_bb0505","doi-asserted-by":"crossref","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","author":"Wang","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103687_bb0510","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(24)00424-0","article-title":"CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis","volume":"403","author":"Krickau","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2024.103687_bb0515","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12969-024-00990-4","article-title":"CAR T cell therapy for refractory pediatric systemic lupus erythematosus: a new era of hope?","volume":"22","author":"Stojkic","year":"2024","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.autrev.2024.103687_bb0520","doi-asserted-by":"crossref","first-page":"e780","DOI":"10.1016\/S2352-3026(24)00209-6","article-title":"Sexual health-related psychological and emotional life after allogeneic haematopoietic stem-cell transplantation","volume":"11","author":"Alsuliman","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.autrev.2024.103687_bb0525","doi-asserted-by":"crossref","first-page":"e770","DOI":"10.1016\/S2352-3026(24)00208-4","article-title":"Sexual health and emotional wellbeing of patients with haematological malignancies: general review","volume":"11","author":"Alsuliman","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.autrev.2024.103687_bb0530","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jtct.2022.10.004","article-title":"Successful generation of CD19 chimeric antigen receptor T cells from patients with advanced systemic lupus erythematosus","volume":"29","author":"Kretschmann","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.autrev.2024.103687_bb0535","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keae108","article-title":"CAR-T cell therapy in systemic lupus erythematosus and beyond: a brave new world?","author":"Van Leuven","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2024.103687_bb0540","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaip.2021.10.037","article-title":"Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions","volume":"10","author":"Wat","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.autrev.2024.103687_bb0545","article-title":"How I treat cytopenias after CAR T-cell therapy","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2024.103687_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101136","article-title":"Access to CAR T-cell therapy: focus on diversity, equity and inclusion","volume":"63","author":"Odstrcil","year":"2024","journal-title":"Blood Rev"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224001782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224001782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T22:14:28Z","timestamp":1732659268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997224001782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":110,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1568997224001782"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103687","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Harnessing the potential of CAR-T cell in lupus treatment: From theory to practice","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103687","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103687"}}